Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1987 Nov 1;166(5):1510–1524. doi: 10.1084/jem.166.5.1510

Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals

PMCID: PMC2189650  PMID: 3681191

Abstract

The Vi has proven to be a protective antigen in two double masked, controlled clinical trials in areas with high rates of typhoid fever (approximately 1% per annum). In both studies the protective efficacy of the Vi was approximately 70%. Approximately 75% of subjects in these areas responded with a fourfold or greater rise of serum Vi antibodies. In contrast, the Vi elicited a fourfold or greater rise in 95-100% of young adults in France and the United States. Methods were devised, therefore, to synthesize Vi-protein conjugates in order to both enhance the antibody response and confer T-dependent properties to the Vi (and theoretically increase its protective action in populations at high risk for typhoid fever). We settled on a method that used the heterobifunctional crosslinking reagent, N-succinimidyl-3-(2- pyridyldithio)-propionate (SPDP), to bind thiol derivatives of the Vi to proteins. This synthetic scheme was reproducible, provided high yields of Vi-protein conjugates, and was applicable to several medically relevant proteins such as diphtheria and tetanus toxoids. The resultant conjugates were more immunogenic in mice and juvenile Rhesus monkeys than the Vi alone. In contrast to the T-independent properties of the Vi, conjugates of this polysaccharide with several medically relevant proteins induced booster responses in mice and in juvenile Rhesus monkeys. Clinical studies with Vi-protein conjugates are planned. This scheme is also applicable to synthesize protein conjugates with other polysaccharides that have carboxyl functions.

Full Text

The Full Text of this article is available as a PDF (1,016.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P. W., Pichichero M. E., Insel R. A., Betts R., Eby R., Smith D. H. Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant. J Immunol. 1986 Aug 15;137(4):1181–1186. [PubMed] [Google Scholar]
  2. Anderson P., Pitt J., Smith D. H. Synthesis and release of polyribophosphate by Haemophilus influenzae type b in vitro. Infect Immun. 1976 Feb;13(2):581–589. doi: 10.1128/iai.13.2.581-589.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  4. Brodie J. Antibodies and the Aberdeen typhoid outbreak of 1964. I. The Widal reaction. J Hyg (Lond) 1977 Oct;79(2):161–180. doi: 10.1017/s0022172400052979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Carlsson J., Drevin H., Axén R. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem J. 1978 Sep 1;173(3):723–737. doi: 10.1042/bj1730723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chisari F. V., Northrup R. S., Chen L. C. The modulating effect of cholera enterotoxin on the immune response. J Immunol. 1974 Sep;113(3):729–739. [PubMed] [Google Scholar]
  7. Chu C., Schneerson R., Robbins J. B., Rastogi S. C. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun. 1983 Apr;40(1):245–256. doi: 10.1128/iai.40.1.245-256.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Craig J. P. A permeability factor (toxin) found in cholera stools and culture filtrates and its neutralization by convalescent cholera sera. Nature. 1965 Aug 7;207(997):614–616. doi: 10.1038/207614a0. [DOI] [PubMed] [Google Scholar]
  9. ELLMAN G. L. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959 May;82(1):70–77. doi: 10.1016/0003-9861(59)90090-6. [DOI] [PubMed] [Google Scholar]
  10. Edelman R., Levine M. M. Summary of an international workshop on typhoid fever. Rev Infect Dis. 1986 May-Jun;8(3):329–349. doi: 10.1093/clinids/8.3.329. [DOI] [PubMed] [Google Scholar]
  11. Elson C. O., Ealding W. Genetic control of the murine immune response to cholera toxin. J Immunol. 1985 Aug;135(2):930–932. [PubMed] [Google Scholar]
  12. Fong S., Nitecki D. E., Cook R. M., Goodman J. W. Spatial requirements between haptenic and carrier determinants for T-dependent antibody responses. J Exp Med. 1978 Sep 1;148(3):817–822. doi: 10.1084/jem.148.3.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fowler B., Robins A. J. Methods for the quantitative analysis of sulphur-containing compounds in physiological fluids. J Chromatogr. 1972 Oct 5;72(1):105–111. doi: 10.1016/0021-9673(72)80012-8. [DOI] [PubMed] [Google Scholar]
  14. GAINES S., CURRIE J. A., TULLY J. G. PRODUCTION OF INCOMPLETE VI ANTIBODY IN MAN BY TYPHOID VACCINE. Am J Epidemiol. 1965 May;81:350–355. doi: 10.1093/oxfordjournals.aje.a120521. [DOI] [PubMed] [Google Scholar]
  15. GAINES S., CURRIE J. A., TULLY J. G. Production of incomplete Vi antibody in mice. Proc Soc Exp Biol Med. 1960 Aug-Sep;104:602–605. doi: 10.3181/00379727-104-25921. [DOI] [PubMed] [Google Scholar]
  16. GAINES S., LANDY M., EDSALL G., MANDEL A. D., TRAPANI R. J., BENENSON A. S. Studies on infection and immunity in experimental typhoid fever. III. Effect of prophylactic immunization. J Exp Med. 1961 Sep 1;114:327–342. doi: 10.1084/jem.114.3.327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gotschlich E. C., Rey M., Etienne J., Sanborn W. R., Triau R., Cvjetanović B. The immunological responses observed in field studies in Africa with group A meningococcal vaccines. Prog Immunobiol Stand. 1971;5:485–491. [PubMed] [Google Scholar]
  18. Hornick R. B. Selective primary health care: strategies for control of disease in the developing world. XX. Typhoid fever. Rev Infect Dis. 1985 Jul-Aug;7(4):536–546. doi: 10.1093/clinids/7.4.536. [DOI] [PubMed] [Google Scholar]
  19. Hornick R. B., Woodward T. E. Appraisal of typhoid vaccine in experimentally infected human subjects. Trans Am Clin Climatol Assoc. 1967;78:70–78. [PMC free article] [PubMed] [Google Scholar]
  20. Islam A., Butler T., Ward L. R. Reinfection with a different Vi-phage type of Salmonella typhi in an endemic area. J Infect Dis. 1987 Jan;155(1):155–156. doi: 10.1093/infdis/155.1.155. [DOI] [PubMed] [Google Scholar]
  21. Jörbeck H. J., Svenson S. B., Lindberg A. A. Artificial Salmonella vaccines: Salmonella typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit opsonizing antibodies that enhance phagocytosis. Infect Immun. 1981 May;32(2):497–502. doi: 10.1128/iai.32.2.497-502.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Katz M., Papenheimer A. M., Jr Quantitative studies of the specificity of anti-pneumococcal antibodies, types 3 and 8. IV. Binding of labeled hexasaccharides derived from S3 by anti-S3 antibodies and their Fab fragments. J Immunol. 1969 Sep;103(3):491–495. [PubMed] [Google Scholar]
  23. Kawata Y. A study of the molecular types of immunoglobulin. II. Mouse protection study of Vi antibody against typhoid infection. Acta Sch Med Univ Kioto. 1970 Mar;40(3):284–290. [PubMed] [Google Scholar]
  24. Komatsu T., Lawn C. Y., Amsden A., Leskowitz S. Hapten-specific T cell response to azobenzenearsonate-N-acetyl-L-tyrosine in the Lewis rat. III. Effects of peptide-spacer structure on eliciting ABA-specific helper activity with TNP-haptened ABA-peptide-Ficoll. J Immunol. 1983 Feb;130(2):586–589. [PubMed] [Google Scholar]
  25. LANDY M. Studies on Vi antigen. VI. Immunization of human beings with purified Vi antigen. Am J Hyg. 1954 Jul;60(1):52–62. doi: 10.1093/oxfordjournals.aje.a119703. [DOI] [PubMed] [Google Scholar]
  26. Lanata C. F., Levine M. M., Ristori C., Black R. E., Jimenez L., Salcedo M., Garcia J., Sotomayor V. Vi serology in detection of chronic Salmonella typhi carriers in an endemic area. Lancet. 1983 Aug 20;2(8347):441–443. doi: 10.1016/s0140-6736(83)90401-4. [DOI] [PubMed] [Google Scholar]
  27. Levine M. M., Ferreccio C., Black R. E., Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1987 May 9;1(8541):1049–1052. doi: 10.1016/s0140-6736(87)90480-6. [DOI] [PubMed] [Google Scholar]
  28. Liau D. F., Melly M. A., Hash J. H. Surface polysaccharide from Staphylococcus aureus M that contains taurine, D-aminogalacturonic acid, and D-fucosamine. J Bacteriol. 1974 Sep;119(3):913–922. doi: 10.1128/jb.119.3.913-922.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. MARMION D. E., NAYLOR G. R., STEWART I. O. Second attacks of typhoid fever. J Hyg (Lond) 1953 Jun;51(2):260–267. doi: 10.1017/s0022172400015680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Nolan C. M., Feeley J. C., White P. C., Jr, Hambie E. A., Brown S. L., Wong K. H. Evaluation of a new assay for Vi antibody in chronic carriers of Salmonella typhi. J Clin Microbiol. 1980 Jul;12(1):22–26. doi: 10.1128/jcm.12.1.22-26.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Reingold A. L., Broome C. V., Hightower A. W., Ajello G. W., Bolan G. A., Adamsbaum C., Jones E. E., Phillips C., Tiendrebeogo H., Yada A. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985 Jul 20;2(8447):114–118. doi: 10.1016/s0140-6736(85)90224-7. [DOI] [PubMed] [Google Scholar]
  32. Robbins J. B. Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future. Immunochemistry. 1978 Nov;15(10-11):839–854. doi: 10.1016/0161-5890(78)90117-7. [DOI] [PubMed] [Google Scholar]
  33. Schneerson R., Barrera O., Sutton A., Robbins J. B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 1980 Aug 1;152(2):361–376. doi: 10.1084/jem.152.2.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Schneerson R., Robbins J. B., Chu C., Sutton A., Vann W., Vickers J. C., London W. T., Curfman B., Hardegree M. C., Shiloach J. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates. Infect Immun. 1984 Sep;45(3):582–591. doi: 10.1128/iai.45.3.582-591.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Szu S. C., Schneerson R., Robbins J. B. Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci. Infect Immun. 1986 Nov;54(2):448–455. doi: 10.1128/iai.54.2.448-455.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Szu S. C., Zon G., Schneerson R., Robbins J. B. Ultrasonic irradiation of bacterial polysaccharides. Characterization of the depolymerized products and some applications of the process. Carbohydr Res. 1986 Sep 1;152:7–20. doi: 10.1016/s0008-6215(00)90283-0. [DOI] [PubMed] [Google Scholar]
  37. Tacket C. O., Ferreccio C., Robbins J. B., Tsai C. M., Schulz D., Cadoz M., Goudeau A., Levine M. M. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis. 1986 Aug;154(2):342–345. doi: 10.1093/infdis/154.2.342. [DOI] [PubMed] [Google Scholar]
  38. Tsai C. M. The analysis of lipopolysaccharide (endotoxin) in meningococcal polysaccharide vaccines by silver staining following SDS-polyacrylamide gel electrophoresis. J Biol Stand. 1986 Jan;14(1):25–33. doi: 10.1016/s0092-1157(86)80006-3. [DOI] [PubMed] [Google Scholar]
  39. Tsang R. S., Chau P. Y. Production of Vi monoclonal antibodies and their application as diagnostic reagents. J Clin Microbiol. 1987 Mar;25(3):531–535. doi: 10.1128/jcm.25.3.531-535.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. WHITESIDE R. E., BAKER E. E. The Vi antigens of the Enterobacteriaceae. V. Serologic differences of Vi antigens revealed by deacetylation. J Immunol. 1961 May;86:538–542. [PubMed] [Google Scholar]
  41. Williamson W. A., Greenwood B. M. Impairment of the immune response to vaccination after acute malaria. Lancet. 1978 Jun 24;1(8078):1328–1329. doi: 10.1016/s0140-6736(78)92403-0. [DOI] [PubMed] [Google Scholar]
  42. Wong K. H., Feeley J. C. Isolation of Vi antigen and a simple method for its measurement. Appl Microbiol. 1972 Oct;24(4):628–633. doi: 10.1128/am.24.4.628-633.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES